Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index

作者：Man Zhao, Xiaoling Duan, Lili Mi, Jianfei Shi, Ning Li, Xiaolei Yin, Xin Han, Jinfeng Wang, Guangjie Han, Jiaojiao Hou, Fei Yin · 发表于：Future Oncology · 年份：2022 · DOI：10.2217/fon-2021-1087 · 被引用次数：30 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Cancer Immunotherapy and Biomarkers、Cancer, Lipids, and Metabolism

Aim: To explore the prognostic value of the systemic inflammatory response index (SIRI) and peripheral blood T-cell subsets in patients with hepatocellular carcinoma (HCC) and the relationship between them. Materials & methods: We treated 352 patients with HCC with sorafenib and/or immune checkpoint inhibitors (ICIs) and analyzed SIRI and peripheral blood T cells. Results: SIRI was an independent prognostic factor for patients with HCC receiving systemic therapy. Patients with high SIRI and low baseline peripheral blood T-cell counts showed a poor response to ICIs. SIRI was significantly and negatively correlated with CD3+, CD4+ and CD8+ T-cell counts. Conclusion: SIRI markers can be employed to noninvasively assess the presence of cancer-promoting inflammation in the tumor microenvironment and predict the efficacy of targeted therapy and immunotherapy.